Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world zanubrutinib treatment patterns in CLL/SLL among a curated sample of US community oncology patients with prior acalabrutinib therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

RCRushir J. ChoksiXWXiaogang WangBCBeverly Chigarira

Discussion

Loading...

Member takes

Overview

Retrospective cohort assessed treatment patterns and discontinuation reasons for CLL patients after switching from acalabrutinib to zanubrutinib, highlighting toxicity as a primary reason.

Key Points

  • This research aims to investigate treatment patterns and reasons for discontinuation in CLL patients who switched from acalabrutinib to zanubrutinib.
  • Used the IntegraConnect PrecisionQ database for a retrospective cohort study
  • Identified CLL/SLL patients who changed therapies
  • Conducted medical record review to assess treatment initiation, discontinuation, and reasons
  • 806 patients initiated acalabrutinib, with 121 switching to zanubrutinib
  • 72.5% of patients received acalabrutinib in first-line treatment
  • Key reasons for acalabrutinib discontinuation included toxicity (68.6%) and disease progression (6.9%)

Cite This Study

Choksi et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2ffhttps://doi.org/10.1182/blood-2025-8041
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world chronic lymphocytic leukemia/small lymphocytic lymphoma treatment patterns at Florida cancer specialists & research institute among patients receiving zanubrutinib immediately following prior BTKi therapy2025
  2. 2Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia2026
  3. 3Adverse event profiles of acalabrutinib and zanubrutinib in chronic lymphocytic leukemia: A real-world comparison2025 · 1 citations
  4. 4Real world outcomes of zanubrutinib monotherapy for CLL/SLL focusing on treatment discontinuation and BTKi switching: A single center retrospective analysis2025
  5. 5Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in US community oncology practices.2024 · 2 citations